Navigation Links
AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
Date:11/29/2007

WILMINGTON, Del., Nov. 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX(R) (anastrozole) for its licensed breast cancer indications until June 2010. Prior to pediatric exclusivity being granted by the FDA, the patent was due to expire in December 2009.

ARIMIDEX is currently approved in the US for the for the following indications:

-- The adjuvant treatment (treatment following surgery with or without

radiation) of postmenopausal women with hormone receptor positive early

breast cancer (Sub Part H approval granted in 2002, final approval in

2005).

-- The first-line treatment of postmenopausal women with hormone receptor

positive or hormone receptor unknown locally advanced or metastatic

breast cancer (granted in 2000).

-- The treatment of advanced breast cancer in postmenopausal women with

disease progression following tamoxifen therapy. Patients with hormone

receptor-negative disease and patients who did not previously respond

to tamoxifen therapy rarely responded to ARIMIDEX (granted in 1995).

Dr. John Patterson, Executive Director of Development at AstraZeneca said "Pre-clinical and clinical data supported the investigation of the therapeutic potential of ARIMIDEX in pediatric conditions that manifest symptoms resulting from increased estrogen production, for example: gynecomastia in pubertal boys and precocious puberty in girls with McCune-Albright Syndrome (MAS). While pleased to have been able to work with the FDA in investigating the potential benefits of ARIMIDEX in these settings, AstraZeneca will not be seeking an indication in either of these pediatric conditions based on trial results."

In the US, ARIMIDEX sales reached $507 million for the nine months of 2007. ARIMIDEX has a
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AstraZeneca Leads Local Walking Movement
2. AstraZeneca Joins Local Walking Movement
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
5. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
6. AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
11. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 For electronic publishing expert eBooks2go, ... down to a miraculous connection and precision timing. This ... while, but over the past three decades, Ms. Wixom ... was finding it rather tedious to expand her readership ... A phone call, an anniversary, and a second-place trophy ...
(Date:9/17/2014)... Wa (PRWEB) September 17, 2014 Diabetes ... by the Telegraph in August 2014, scientists made ... for diabetes, but still failed. The article indicates that ... Despite this existing fact, there are many forward-thinking entrepreneurs ... diabetes treatment in a natural way. Dr. Kenneth Pullman ...
(Date:9/17/2014)... ICS Learning Group, Inc. won a coveted ... for the Best Use of Games and Simulations for ... operational safety training module that ICS developed for one ... an approach that combined realistic 3D simulation with gamification, ... to a video game, including competition among trainees, to ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Health.Verticalize, a ... people explore their health insurance options in the 2014 ... Network. , Moving forward Health Network ... website. The company has intentionally remained out of the ... network from a single website to its present position ...
(Date:9/16/2014)... Recently, BamboofloorChina.com, the popular online supplier ... of strand woven bamboo floors to its ... big promotion for the new items; the current discount ... is a great shopping season. Therefore, BamboofloorChina.com spares no ... new customers. All practical items offered by BamboofloorChina.com are ...
Breaking Medicine News(10 mins):Health News:Versatile Author Wixom Forges Lasting Relationship with Digital Virtuoso eBooks2go 2Health News:Versatile Author Wixom Forges Lasting Relationship with Digital Virtuoso eBooks2go 3Health News:Versatile Author Wixom Forges Lasting Relationship with Digital Virtuoso eBooks2go 4Health News:Discover a Safe and Effective Treatment for Diabetes with The Diabetes Protocol – Vinamy 2Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 3Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2
... , EMERYVILLE, Calif., Sept. 21 Bionovo, Inc. (Nasdaq: ... the company received a letter from NASDAQ stating that, for the ... stock has closed below the minimum $1.00 per share requirement for ... that the company has been provided a period of 180 calendar ...
... , , , ... Medical, Inc. has made a $15 million equity investment in the company. ... officer of Micell, said, "We are excited to have a company of ... forward to collaborating with them to expand the use of our coating ...
... , , BELMONT, Calif., ... focused on improving the lives of patients with sleep-disordered breathing, ... the Runners-Up Award in The Wall Street Journal ... were published in the September 14, 2009 edition of ...
... results seen with both open surgery and minimally invasive ... -- Successful repair of nasal fractures is possible using ... long as the procedure is appropriate for the type ... be selected by taking into account factors such as ...
... American Gastroenterological Association (AGA) Foundation for Digestive Health and ... businessman and photographer, Bernard Lee Schwartz, has honored his ... for pancreatic cancer research. The $225,000 gift from the ... with funding and protected time for three years to ...
... A multicenter study in Asia found drug-eluting stents ... patients with chronic total occlusions (CTOs) undergoing PCI. Results ... annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by ... the study, "Drug-Eluting Stents for the Treatment of Chronic ...
Cached Medicine News:Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 2Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 3Health News:Ventus Medical Announces PROVENT(R) Sleep Apnea Therapy Recognized by The Wall Street Journal 2009 Technology Innovation Awards 2Health News:Ventus Medical Announces PROVENT(R) Sleep Apnea Therapy Recognized by The Wall Street Journal 2009 Technology Innovation Awards 3Health News:Best Option for Fractured Nose Varies by Patient 2Health News:California family honors father with second AGA Foundation Research Scholar Award 2Health News:Drug-eluting stents safe, effective for treatment of chronic total occlusions 2
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that agreement has ... Administration (FDA) on the design of a pivotal, ... (synthetic hypericin) for the treatment of cutaneous T-cell ...
(Date:9/16/2014)... September 2014 Hologic, Inc. ... heute die Markteinführung des Tomcat, einem ... Europa bekannt gegeben. Der Tomcat ist ... Vereinfachung der präanalytischen Probenverarbeitung. Dies wird ... Arbeitsschritte bei der manuellen Aliquotierung von ...
(Date:9/16/2014)... MEMPHIS, Tenn. , Sept. 16, 2014 ... Hospital investigators has found the chemotherapy dose threshold ... have normal sperm production. The study appears in September ... By clarifying which patients are at highest ... the findings to eventually increase use of pre-treatment fertility ...
Breaking Medicine Technology:Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 3Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... TORONTO, Sept. 28 According to Millennium Research Group ... the European gastric band device market was valued at ... end of 2015.  Increased awareness of health issues surrounding ... rising European obesity rates, will drive significant growth in ...
... Cobalis Corp. (Pink Sheets: CLSC ) is ... and shareholders with further details and the latest updates about ... Shareholders and investors MUST RSVP to participate in this ... 1:15pm Pacific Time. Interested parties may RSVP to participate in ...
Cached Medicine Technology:While Ethicon Endo-Surgery and Allergan Remain Front-Runners in the $41 Million Gastric Band Market, Other Competitors Battle for Third Place, According to Millennium Research Group 2Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2
... thin collagen coated highly compliant ... thin wall construction offers optimal ... Hemacarotid UltraThin Patch provides superb ... and healing, without suture hole ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
Medicine Products: